Want to see SER full AI Analyst Report?
Serina Therapeutics (SER) Stock Statistics & Valuation Metrics
Total Valuation
Serina Therapeutics has a market cap or net worth of $49.28M. The enterprise value is $11.97M.
- Market Cap
- $49.28M
- Enterprise Value
- $11.97M
Share Statistics
Serina Therapeutics has 25,400,473 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 25,400,473
- Owned by Insiders
- 34.84%
- Owned by Institutions
- 1.68%
Financial Efficiency
Serina Therapeutics’s return on equity (ROE) is 518.43 and return on invested capital (ROIC) is -709.03%.
- Return on Equity (ROE)
- 518.43
- Return on Assets (ROA)
- -2.76
- Return on Invested Capital (ROIC)
- -709.03%
- Return on Capital Employed (ROCE)
- -7.09
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.20M
- Employee Count
- 16
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Serina Therapeutics is -1.03. Serina Therapeutics’s PEG ratio is 0.02.
- PE Ratio
- -1.03
- PS Ratio
- 0.00
- PB Ratio
- 1.70
- Price to FCF
- -1.37
- Price to Operating Cash Flow
- -1.50
- PEG Ratio
- 0.02
Income Statement
In the last 12 months, Serina Therapeutics had revenue of 0 and earned -19.18M in profits. Earnings per share was -1.91.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -24.02M
- Pretax Income
- -19.20M
- Net Income
- -19.18M
- EBITDA
- -18.91M
- Earnings Per Share (EPS)
- -1.91
Cash Flow
In the last 12 months, operating cash flow was -21.14M and capital expenditures -66,000, giving a free cash flow of -21.17M billion.
- Operating Cash Flow
- -21.14M
- Free Cash Flow
- -21.17M
- Free Cash Flow per Share
- -1.29
Dividends & Yields
Serina Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -72.77%
- Earnings Yield
- -66.62%
Stock Price Statistics
- Beta
- 0.22
- 52-Week Price Change
- -59.50%
- 50-Day Moving Average
- 2.15
- 200-Day Moving Average
- 2.08
- Relative Strength Index (RSI)
- 52.33
- Average Volume (3m)
- 70.20K
Important Dates
Serina Therapeutics upcoming earnings date is Nov 18, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 13, 2026
- Next Earnings Date
- Nov 18, 2026
- Ex-Dividend Date
- ―
Financial Position
Serina Therapeutics as a current ratio of 1.71, with Debt / Equity ratio of -529.73%
- Current Ratio
- 1.71
- Quick Ratio
- 1.71
- Debt to Market Cap
- 0.01
- Net Debt to EBITDA
- 0.15
- Interest Coverage Ratio
- -112.78
Taxes
In the past 12 months, Serina Therapeutics has paid 18.00K in taxes.
- Income Tax
- 18.00K
- Effective Tax Rate
- -0.00
Enterprise Valuation
Serina Therapeutics EV to EBITDA ratio is -0.42, with an EV/FCF ratio of -0.44.
- EV to Sales
- 0.00
- EV to EBITDA
- -0.42
- EV to Free Cash Flow
- -0.44
- EV to Operating Cash Flow
- -0.44
Balance Sheet
Serina Therapeutics has $23.02M in cash and marketable securities with $3.21M in debt, giving a net cash position of $19.82M billion.
- Cash & Marketable Securities
- $23.02M
- Total Debt
- $3.21M
- Net Cash
- $19.82M
- Net Cash Per Share
- $0.78
- Tangible Book Value Per Share
- $1.14
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Serina Therapeutics is $9.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $9.50
- Price Target Upside
- 389.69% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 2
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―
Scores
- Smart Score
- 2
- AI Score
- 44
